143 related articles for article (PubMed ID: 29545343)
1. Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-
Maffini E; Anderson LD; Sandmaier BM; Green DJ; Storer BE; Niederwieser D; Maziarz RT; Maloney DG; Storb R
Haematologica; 2018 Jun; 103(6):e252-e255. PubMed ID: 29545343
[No Abstract] [Full Text] [Related]
2. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.
Cornell RF; Bachanova V; D'Souza A; Woo-Ahn K; Martens M; Huang J; Al-Homsi AS; Chhabra S; Copelan E; Diaz MA; Freytes CO; Gale RP; Ganguly S; Hamadani M; Hildebrandt G; Kamble RT; Kharfan-Dabaja M; Kindwall-Keller T; Lazarus HM; Marks DI; Nishihori T; Olsson RF; Saad A; Usmani S; Vesole DH; Yared J; Mark T; Nieto Y; Hari P
Biol Blood Marrow Transplant; 2017 Jan; 23(1):60-66. PubMed ID: 27789362
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Kyriakou C; Canals C; Cornelissen JJ; Socié G; Willemze R; Ifrah N; Greinix HT; Blaise D; Deconinck E; Ferrant A; Schattenberg A; Harousseau JL; Sureda A; Schmitz N
J Clin Oncol; 2010 Nov; 28(33):4926-34. PubMed ID: 20956626
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
[TBL] [Abstract][Full Text] [Related]
5. Management of refractory autoimmune hemolytic anemia via allogeneic stem cell transplantation.
Rotenstein L; Nathan A; Ghobrial I; Antin J; Parnes A
Bone Marrow Transplant; 2016 Nov; 51(11):1504-1506. PubMed ID: 27272445
[No Abstract] [Full Text] [Related]
6. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinemia with severe pancytopenia.
Ueda T; Hatanaka K; Kosugi S; Kishino BI; Tamaki T
Bone Marrow Transplant; 2001 Sep; 28(6):609-11. PubMed ID: 11607775
[TBL] [Abstract][Full Text] [Related]
7. Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
Eefting M; von dem Borne PA; de Wreede LC; Halkes CJ; Kersting S; Marijt EW; Veelken H; Falkenburg JF
Haematologica; 2014 Apr; 99(4):751-8. PubMed ID: 24241493
[TBL] [Abstract][Full Text] [Related]
8. Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group.
Sakurai M; Mori T; Uchiyama H; Ago H; Iwato K; Eto T; Iwasaki H; Kawata T; Takamatsu H; Yamasaki S; Takanashi M; Ichinohe T; Atsuta Y; Suzuki R
Ann Hematol; 2020 Jul; 99(7):1635-1642. PubMed ID: 32424672
[TBL] [Abstract][Full Text] [Related]
9. Durable remission of large B-cell lymphoma transformed from lymphoplasmacytic lymphoma/Waldenström macroglobulinemia successfully treated with sequential immunochemotherapy followed by reduced-intensity allogeneic stem cell transplantation.
Yamamoto R; Takaori-Kondo A; Kanda J; Imada K; Ichinohe T; Ishikawa T; Ohmori K; Uchiyama T
Bone Marrow Transplant; 2008 Mar; 41(6):591-3. PubMed ID: 18071292
[No Abstract] [Full Text] [Related]
10. Haploidentical
Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
[TBL] [Abstract][Full Text] [Related]
11. High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia.
Kyriakou C
Hematol Oncol Clin North Am; 2018 Oct; 32(5):865-874. PubMed ID: 30190024
[TBL] [Abstract][Full Text] [Related]
12. Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
Xiao X; Huang H; Chen J; Jiang Y; Zhang L; Xu Y; Xu T; Chen X; Li C; Jin Z; Ruan J; Wu D
Leuk Lymphoma; 2017 Dec; 58(12):2957-2961. PubMed ID: 28509575
[No Abstract] [Full Text] [Related]
13. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.
Parrondo RD; Reljic T; Iqbal M; Ayala E; Tun HW; Kharfan-Dabaja MA; Kumar A; Murthy HS
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e694-e711. PubMed ID: 32616401
[TBL] [Abstract][Full Text] [Related]
15. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
Glass B; Hasenkamp J; Wulf G; Dreger P; Pfreundschuh M; Gramatzki M; Silling G; Wilhelm C; Zeis M; Görlitz A; Pfeiffer S; Hilgers R; Truemper L; Schmitz N;
Lancet Oncol; 2014 Jun; 15(7):757-66. PubMed ID: 24827808
[TBL] [Abstract][Full Text] [Related]
16. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
Ahmed S; Zhao Q; Hanel W; Qazilbash MH; Patel K; Narra R; Kansagra A; Iqbal M; Awan FT; Christian B; Jaglowski SM; Kharfan-Dabaja MA; Hamadani M; Epperla N
Hematol Oncol; 2022 Feb; 40(1):48-56. PubMed ID: 34763367
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Garnier A; Robin M; Larosa F; Golmard JL; Le Gouill S; Coiteux V; Tabrizi R; Bulabois CE; Cacheux V; Kuentz M; Dreyfus B; Dreger P; Rio B; Moles-Moreau MP; Bilger K; Bay JO; Leblond V; Blaise D; Tournilhac O; Dhédin N
Haematologica; 2010 Jun; 95(6):950-5. PubMed ID: 20081058
[TBL] [Abstract][Full Text] [Related]
18. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
[TBL] [Abstract][Full Text] [Related]
19. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C
J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328
[TBL] [Abstract][Full Text] [Related]
20. Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience.
Stakiw J; Kim DH; Kuruvilla J; Gupta V; Messner H; Lipton JH
Bone Marrow Transplant; 2007 Aug; 40(4):369-72. PubMed ID: 17589533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
